Virax Biolabs Group Statistics
Total Valuation
VRAX has a market cap or net worth of $2.48 million. The enterprise value is -$421,381.
Important Dates
The last earnings date was Friday, June 12, 2026.
| Earnings Date | Jun 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
VRAX has 796,937 shares outstanding. The number of shares has increased by 70.75% in one year.
| Current Share Class | 796,937 |
| Shares Outstanding | 796,937 |
| Shares Change (YoY) | +70.75% |
| Shares Change (QoQ) | +9.31% |
| Owned by Insiders (%) | 3.64% |
| Owned by Institutions (%) | 0.20% |
| Float | 727,893 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 830.03 |
| Forward PS | n/a |
| PB Ratio | 0.15 |
| P/TBV Ratio | 0.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.35, with a Debt / Equity ratio of 0.11.
| Current Ratio | 11.35 |
| Quick Ratio | 9.89 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -92.32 |
Financial Efficiency
Return on equity (ROE) is -83.82% and return on invested capital (ROIC) is -50.14%.
| Return on Equity (ROE) | -83.82% |
| Return on Assets (ROA) | -48.40% |
| Return on Invested Capital (ROIC) | -50.14% |
| Return on Capital Employed (ROCE) | -109.72% |
| Weighted Average Cost of Capital (WACC) | 10.77% |
| Revenue Per Employee | $157 |
| Profits Per Employee | -$297,031 |
| Employee Count | 19 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.27 |
Taxes
| Income Tax | -273,594 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.63% in the last 52 weeks. The beta is 1.24, so VRAX's price volatility has been higher than the market average.
| Beta (5Y) | 1.24 |
| 52-Week Price Change | -83.63% |
| 50-Day Moving Average | 4.39 |
| 200-Day Moving Average | 8.39 |
| Relative Strength Index (RSI) | 36.55 |
| Average Volume (20 Days) | 169,804 |
Short Selling Information
| Short Interest | 1.07M |
| Short Previous Month | 391,277 |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, VRAX had revenue of $2,986 and -$5.64 million in losses. Loss per share was -$30.94.
| Revenue | 2,986 |
| Gross Profit | -45,306 |
| Operating Income | -5.87M |
| Pretax Income | -5.93M |
| Net Income | -5.64M |
| EBITDA | -5.56M |
| EBIT | -5.87M |
| Loss Per Share | -$30.94 |
Full Income StatementBalance Sheet
The company has $3.44 million in cash and $537,993 in debt, giving a net cash position of $2.90 million or $3.64 per share.
| Cash & Cash Equivalents | 3.44M |
| Total Debt | 537,993 |
| Net Cash | 2.90M |
| Net Cash Per Share | $3.64 |
| Equity (Book Value) | 5.07M |
| Book Value Per Share | 20.30 |
| Working Capital | 3.78M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$5.41 million and capital expenditures -$497,400, giving a free cash flow of -$5.90 million.
| Operating Cash Flow | -5.41M |
| Capital Expenditures | -497,400 |
| Depreciation & Amortization | 312,984 |
| Net Borrowing | -108,594 |
| Free Cash Flow | -5.90M |
| FCF Per Share | -$7.41 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -196,566.68% |
| Pretax Margin | -198,510.88% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |